Director/PDMR Shareholding

25 Jul 2007 16:42

Akers Biosciences, Inc.25 July 2007 Akers Biosciences, Inc. ("ABI" or the "Company") Employee Shareholding & Additional Listing Akers Biosciences, Inc. which develops, manufactures, and supplies rapid, pointof care screening and testing products announces that Company employees have, on24 July 2007, increased their shareholdings in the Company by way of asubscription to New Ordinary shares. Patrice McMorrow, Director of Marketing, has invested $4,715 by way of asubscription to 20,000 New Ordinary Shares at yesterday's closing price of 11.50pence. Ms. McMorrow's shareholdings now total 20,000 common shares, representingless than .001% of the total issued share capital of the Company. Anna Marie Arzillo, Assistant Corporate Secretary, has invested $4,715 by way ofa subscription to 20,000 New Ordinary Shares at yesterday's closing price of11.50 pence. Ms. Arzillo's shareholdings now total 20,000 common shares,representing less than .001% of the total issued share capital of the Company. Barbara A. Bagby, Director of Regulatory Affairs, has invested $4,715 by way ofa subscription to 20,000 New Ordinary Shares at yesterday's closing price of11.50 pence. Ms. Bagby's shareholdings now total 20,000 common shares,representing less than .001% of the total issued share capital of the Company. Robert J. Paratore, Financial Controller, has invested $2,357 by way of asubscription to 10,000 New Ordinary Shares at yesterday's closing price of 11.50pence. Mr. Paratore's shareholdings now total 10,000 common shares,representing less than .001% of the total issued share capital of the Company. Carl E. King, Director BreathScan Division, has invested $2,357 by way of asubscription to 10,000 New Ordinary Shares at yesterday's closing price of 11.50pence. Mr. King's shareholdings now total 10,000 common shares, representingless than .001% of the total issued share capital of the Company. Application has been made to the London Stock Exchange for 80,000 New OrdinaryShares, which will rank pari passu with existing Ordinary Shares, to be admittedto trading, such admission expected to take place on 1 August 2007. The exchange rate used for these transactions was $2.05:£1.00. Enquiries: Thomas A. Nicolette, President & CFO Akers Biosciences, Inc. Tel. 001 856 848 8698 Ben Simons Hansard Group Tel. 020 7245 1100 This information is provided by RNS The company news service from the London Stock Exchange